Five industries are poised to drive Sydney’s economic future, with new forecasts showing finance, biotech, digital-tech, ...

Monopar Therapeutics (MNPR) announced that it has entered into an agreement with Alexion, AstraZeneca (AZN) Rare Disease for an exclusive ...

Vanguard Renewables, a portfolio company of Global Infrastructure Partners (GIP), a part of BlackRock, has held a ...

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

Monopar Therapeutics shares rose after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion. Shares of the Wilmette, Ill., ...

Monopar Therapeutics (MNPR) surges 20% pre-market after entering exclusive agreement with Alexion, AstraZeneca for Wilson ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront in the form of a cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and ...

Atrial fibrillation is a key risk factor for ischaemic stroke. Furthermore, patients with atrial fibrillation and stroke tend ...

World Business Council for Sustainable Development (WBCSD) is collaborating with leading companies in the sector, with support from PwC UK, to develop a Roadmap to Nature Positive for the ...

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...